panitumumab Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 4955 339177-26-3

Description:

MoleculeDescription

Synonyms:

  • panitumumab
  • vectibix
  • ABX-EGF
Recombinant human monoclonal antibody that binds to and inhibits the function of the EPIDERMAL GROWTH FACTOR RECEPTOR. It is used in the treatment of EGFR-expressing metastatic colorectal cancer that expresses wild-type ras gene (see GENES, RAS).
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 2007 EMA Amgen Europe B.V.
Sept. 27, 2006 FDA AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 827.66 26.57 183 8328 3887 46673664
Paronychia 418.99 26.57 108 8403 4458 46673093
Skin toxicity 377.40 26.57 95 8416 3559 46673992
Hypomagnesaemia 305.21 26.57 124 8387 22086 46655465
Stomatitis 244.44 26.57 153 8358 68144 46609407
Dry skin 232.52 26.57 124 8387 40892 46636659
Rash 230.27 26.57 302 8209 356210 46321341
Skin fissures 178.44 26.57 63 8448 7617 46669934
Colorectal cancer metastatic 177.61 26.57 38 8473 682 46676869
Neutropenia 160.92 26.57 162 8349 143042 46534509
Colon cancer 159.66 26.57 61 8450 9208 46668343
Colorectal cancer 151.16 26.57 35 8476 912 46676639
Disease progression 148.44 26.57 127 8384 91173 46586378
Diarrhoea 144.88 26.57 315 8196 559287 46118264
Neuropathy peripheral 126.89 26.57 116 8395 90777 46586774
Neurotoxicity 99.42 26.57 49 8462 13668 46663883
Skin disorder 97.83 26.57 57 8454 22206 46655345
Palmar-plantar erythrodysaesthesia syndrome 86.27 26.57 51 8460 20400 46657151
Neutrophil count decreased 82.08 26.57 66 8445 43360 46634191
Peripheral sensory neuropathy 80.86 26.57 34 8477 6569 46670982
Rash pustular 79.28 26.57 34 8477 6895 46670656
Metastases to liver 77.82 26.57 47 8464 19538 46658013
Mucosal inflammation 77.43 26.57 61 8450 38915 46638636
Drug ineffective 67.79 26.57 20 8491 677818 45999733
Hypertrichosis 65.97 26.57 18 8493 922 46676629
Skin reaction 64.46 26.57 34 8477 10912 46666639
Adenocarcinoma of colon 59.15 26.57 20 8491 2120 46675431
Malignant neoplasm progression 57.71 26.57 65 8446 64861 46612690
Xerosis 57.45 26.57 15 8496 648 46676903
Acne 57.29 26.57 39 8472 19880 46657671
Hypocalcaemia 49.08 26.57 40 8471 26745 46650806
Febrile neutropenia 48.30 26.57 72 8439 94555 46582996
Blood magnesium decreased 47.88 26.57 28 8483 10964 46666587
Hypokalaemia 46.40 26.57 68 8443 87956 46589595
Decreased appetite 43.88 26.57 104 8407 193732 46483819
Dehydration 43.26 26.57 92 8419 159448 46518103
Carcinoembryonic antigen increased 42.24 26.57 14 8497 1395 46676156
Thrombocytopenia 41.48 26.57 79 8432 126502 46551049
Polyneuropathy 41.30 26.57 26 8485 11618 46665933
Trichomegaly 40.91 26.57 7 8504 34 46677517
Fall 38.12 26.57 7 8504 329090 46348461
Conjunctivitis 36.92 26.57 27 8484 15397 46662154
Growth of eyelashes 36.01 26.57 8 8503 172 46677379
Anaemia 34.81 26.57 114 8397 255665 46421886
Ileus 34.53 26.57 25 8486 14039 46663512
Folliculitis 32.96 26.57 18 8493 6185 46671366
Gastrointestinal toxicity 32.95 26.57 16 8495 4315 46673236
Death 32.56 26.57 134 8377 335414 46342137
Arthralgia 32.42 26.57 13 8498 364590 46312961
Interstitial lung disease 31.83 26.57 44 8467 53905 46623646
Headache 31.20 26.57 25 8486 478327 46199224
Eye irritation 30.83 26.57 25 8486 16589 46660962
Erythema 29.47 26.57 74 8437 142746 46534805
Pain of skin 29.25 26.57 18 8493 7724 46669827
Haematotoxicity 28.46 26.57 17 8494 6916 46670635
Dermatitis 27.68 26.57 22 8489 14186 46663365

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 1686.96 25.72 413 13339 5276 29933450
Paronychia 944.44 25.72 229 13523 2782 29935944
Skin toxicity 656.67 25.72 174 13578 3075 29935651
Hypomagnesaemia 556.25 25.72 228 13524 16370 29922356
Rash 418.92 25.72 475 13277 191414 29747312
Colorectal cancer 401.27 25.72 104 13648 1675 29937051
Stomatitis 324.92 25.72 206 13546 37073 29901653
Skin reaction 301.51 25.72 103 13649 4422 29934304
Rash pustular 265.34 25.72 96 13656 4887 29933839
Interstitial lung disease 252.92 25.72 214 13538 59983 29878743
Colon cancer 223.54 25.72 98 13654 8274 29930452
Dry skin 223.13 25.72 135 13617 22319 29916407
Colorectal cancer metastatic 218.29 25.72 57 13695 945 29937781
Disease progression 215.68 25.72 222 13530 79652 29859074
Diarrhoea 213.38 25.72 470 13282 333633 29605093
Metastases to liver 187.30 25.72 97 13655 11868 29926858
Acne 178.56 25.72 87 13665 9349 29929377
Neutropenia 166.91 25.72 247 13505 128293 29810433
Skin disorder 161.53 25.72 87 13665 11521 29927205
Neuropathy peripheral 158.61 25.72 178 13574 70297 29868429
Folliculitis 156.64 25.72 60 13692 3580 29935146
Mucosal inflammation 135.24 25.72 112 13640 30382 29908344
Decreased appetite 107.67 25.72 222 13530 149688 29789038
Skin fissures 107.39 25.72 45 13707 3394 29935332
Conjunctivitis 94.92 25.72 54 13698 7946 29930780
Neutrophil count decreased 89.89 25.72 104 13648 42350 29896376
Carcinoembryonic antigen increased 86.02 25.72 25 13727 625 29938101
Drug ineffective 84.27 25.72 26 13726 340361 29598365
Palmar-plantar erythrodysaesthesia syndrome 83.94 25.72 63 13689 14807 29923919
Metastases to lung 82.30 25.72 49 13703 7846 29930880
Hypocalcaemia 77.47 25.72 70 13682 21306 29917420
Peripheral sensory neuropathy 73.16 25.72 41 13711 5860 29932866
Xerosis 69.47 25.72 20 13732 483 29938243
Blood magnesium decreased 65.01 25.72 37 13715 5446 29933280
Neurotoxicity 61.70 25.72 50 13702 13132 29925594
Polyneuropathy 59.94 25.72 47 13705 11776 29926950
Therapy partial responder 52.25 25.72 28 13724 3663 29935063
Drug interaction 51.55 25.72 14 13738 199554 29739172
Thrombocytopenia 50.73 25.72 158 13594 136886 29801840
Headache 50.57 25.72 11 13741 182295 29756431
Erythema 49.98 25.72 110 13642 77341 29861385
Dermatitis 49.31 25.72 36 13716 8106 29930620
Ileus 48.76 25.72 47 13705 15508 29923218
Growth of eyelashes 47.73 25.72 10 13742 58 29938668
Dehydration 45.30 25.72 142 13610 123397 29815329
Metastases to pelvis 43.36 25.72 12 13740 250 29938476
Perioral dermatitis 42.50 25.72 10 13742 105 29938621
Catheter site thrombosis 41.70 25.72 8 13744 27 29938699
Febrile neutropenia 41.30 25.72 125 13627 106568 29832158
Hepatectomy 40.90 25.72 9 13743 68 29938658
Arthralgia 40.15 25.72 7 13745 135784 29802942
Carbohydrate antigen 19-9 increased 37.10 25.72 10 13742 188 29938538
Pulmonary embolism 36.50 25.72 98 13654 78037 29860689
Rectal cancer 35.05 25.72 18 13734 2158 29936568
Colorectal cancer recurrent 34.98 25.72 7 13745 31 29938695
Toxicity to various agents 34.86 25.72 19 13733 177164 29761562
Trichomegaly 34.24 25.72 6 13746 10 29938716
Gastrointestinal toxicity 33.48 25.72 17 13735 1991 29936735
Nail disorder 32.55 25.72 16 13736 1749 29936977
Fall 32.30 25.72 22 13730 181850 29756876
Livedo reticularis 31.98 25.72 17 13735 2187 29936539
Somnolence 30.86 25.72 4 13748 96759 29841967
Intestinal obstruction 30.85 25.72 41 13711 19171 29919555
Adenocarcinoma of colon 30.62 25.72 19 13733 3273 29935453
Metastases to lymph nodes 29.71 25.72 20 13732 3957 29934769
Ectropion 29.70 25.72 7 13745 74 29938652
Acne pustular 29.29 25.72 7 13745 79 29938647
Myocardial infarction 28.53 25.72 11 13741 125614 29813112
Epidermal naevus syndrome 28.29 25.72 5 13747 9 29938717
Pain in extremity 27.92 25.72 8 13744 110213 29828513
Colon cancer recurrent 27.09 25.72 7 13745 111 29938615
Dermatitis infected 27.09 25.72 7 13745 111 29938615
Product dose omission issue 26.47 25.72 5 13747 91626 29847100
Enterocolitis 26.40 25.72 23 13729 6664 29932062

Pharmacologic Action:

SourceCodeDescription
ATC L01XC08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Monoclonal antibodies
FDA CS M0001357 Antibodies, Monoclonal
FDA MoA N0000020010 HER1 Antagonists
FDA EPC N0000175664 Epidermal Growth Factor Receptor Antagonist
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Secondary malignant neoplasm of colon indication 94260004

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Epidermal growth factor receptor Kinase AGONIST Kd 10.30 IUPHAR DRUG LABEL

External reference:

IDSource
D05350 KEGG_DRUG
4025701 VUID
N0000179714 NUI
4025701 VANDF
C0879427 UMLSCUI
CHEMBL1201827 ChEMBL_ID
DB01269 DRUGBANK_ID
D000077544 MESH_DESCRIPTOR_UI
6883 IUPHAR_LIGAND_ID
8499 INN_ID
6A901E312A UNII
263034 RXNORM
22205 MMSL
88497 MMSL
d05879 MMSL
011743 NDDF
423259008 SNOMEDCT_US
424401006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-954 SOLUTION 100 mg INTRAVENOUS BLA 28 sections
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-956 SOLUTION 400 mg INTRAVENOUS BLA 28 sections